filibuvir

Filibuvir is an orally available, non-nucleoside small molecule inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. Developed by Pfizer, it was designed for the treatment of hepatitis C infection, specifically targeting genotype 1. Filibuvir binds to the non-catalytic Thumb II allosteric pocket of the NS5B polymerase, leading to a decrease in viral RNA synthesis. It demonstrated potent and selective inhibition in preclinical studies and clinical trials but did not improve sustained virologic response rates when combined with pegylated interferon alfa and ribavirin compared to standard therapy alone. Development was discontinued in 2013 for strategic reasons[1][4][6].

Other names

filibuvirPF-00868554PF00868554PF 00868554PF-868554PF868554PF 868554